Claims for Patent: 8,163,904

Summary for Patent: 8,163,904

Title:	Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-- 3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide
Abstract:	Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]- -3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide are prepared by various processes.
Inventor(s):	Manley; Paul W (Arlesheim, CH), Shieh; Wen-Chung (Berkeley Heights, NJ), Sutton; Paul Allen (Parsippany, NJ), Karpinski; Piotr H (Lincoln Park, NJ), Wu; Raeann (Pine Brook, NJ), Monnier; Stephanie (Raedersheim, FR), Brozio; Jorg (Basel, CH)
Assignee:	Novartis AG (Basel, CH) Novartis Pharma GmbH (Vienna, AT)
Application Number:	11/995,898
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,163,904
Patent Claims:	1. A salt of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyr- idin-3-yl-pyrimidin-2-ylamino)-benzamide, which is 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyr- idin-3-yl-pyrimidin-2-ylamino)-benzamide monohydrochloride. 2. A method of preparing 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyr- idin-3-yl-pyrimidin-2-ylamino)-benzamide monohydrochloride monohydrate comprising the steps of: (a) combining 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyr- idin-3-yl-pyrimidin-2-ylamino)-benzamide free base and hydrochloric acid in methanol under a nitrogen atmosphere; (b) heating the reaction mixture to a temperature ranging from about 42-50.degree. C.; (c) stirring the reaction mixture; (d) filtering the reaction mixture while maintaining the temperature above 40.degree. C. to obtain a clear solution; (e) cooling the clear solution to about 30.degree. C. while stirring under nitrogen atmosphere; (f) seeding the solution; (g) cooling the seeded solution to about 23.degree. C.; (h) stirring the solution to obtain a suspension; (i) cooling the suspension to about -10.degree. C.; (j) stirring the suspension; (k) filtering solids; (l) rinsing solids with cold methanol; and (m) drying the solids at about 50-55.degree. C. and 10-20 torr to obtain 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyr- idin-3-yl-pyrimidin-2-ylamino)-benzamide monohydrochloride monohydrate salt. 3. A pharmaceutical composition comprising: (a) a therapeutically effective amount of a salt according to claim 1; and (b) at least one pharmaceutically acceptable carrier, diluent, vehicle or excipient. 4. A salt according to claim 1 which is 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyr- idin-3-yl-pyrimidin-2-ylamino)-benzamide monohydrochloride monohydrate.